Advocacy

Advocacy in Action

November 19, 2026

Senate Republicans Release NIH Funding Bill with Increase; OMB Rule Remains Uncertain 

This week, the Senate Appropriations Committee released a Republican draft of the Fiscal Year 2027 (FY 2027) Labor- Health and Human Services (L-HHS) bill, which provides funding for the National Institutes of Health (NIH). The bill proposes a budget of $49B for NIH, which is an increase of $500 million above FY 2026 levels. Most Institutes and Centers (ICs) within NIH received level funding relative to the previous fiscal year, but some ICs that provide funding for endocrine-related priorities received targeted increases. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), for example, received an increase of $25 million for diabetes research in FY 2027, raising the total level of proposed funding to $2.351B. Similarly, the bill proposes a $10 million increase in funding for the Office of Research on Women’s Health for a total of $116.480 million. $913 million is proposed for the National Institute of Environmental Health Sciences (NIEHS), maintaining the same level of funding as FY 2026. Consistent with our advocacy priorities and in the FY 2026 L-HHS bill, the bill contains language that keeps the proportion of multi-year funded awards in FY 2027 compared to FY 2025. Unfortunately, the bill does not include language that would block the implementation of the OMB proposed rule.

The bill’s proposed NIH funding increase is welcome, but the measure reflects only the current majority party’s priorities. Both parties support NIH and share concerns about the proposed OMB rule’s impact. With government funding set to expire at 11:59 p.m. on December 11, we expect the House and Senate to pass another short-term funding bill, known as a continuing resolution, to keep the government funded into March. The new Congress will then have to finish work on all 12 funding bills. The current and incoming chairs of the House and Senate Appropriations Committees have also signaled growing bipartisan support for addressing the proposed rule.

Consequently, now is a critical time to contact Congress to support NIH funding and protect NIH research. Join the Endocrine Society’s online advocacy campaign to keep the pressure on Congress to fund the government past December 11 and to block the implementation of the OMB proposed rule.

Diabetes Caucus Co-Chairs Lead Letter Signed by 243 Lawmakers Urging Congress to Reauthorize Special Diabetes Program; Urge Your Members of Congress to Reauthorize SDP & Pass the INSULIN Act 

The Endocrine Society continues to be a leading advocate for continuing funding for the Special Diabetes Program (SDP) and for passage of the INSULIN Act, which will cap out-of-pocket costs for insulin for those with private insurance. This week, the Congressional Diabetes Caucus sent a letter, signed by 243 Members of Congress, to congressional leadership urging them to reauthorize the Special Diabetes Program (SDP) before the Program expires. The letter, which was led by Caucus co-chairs Senator Jeanne Shaheen (D-NH), Senator Susan Collins (R-ME), Representative Diana DeGette (D-CO), and Representative Gus Bilirakis (R-FL), emphasized the importance of passing a multi-year extension of SDP. SDP is a critical program that funds type 1 diabetes research at the National Institutes of Diabetes and Digestive and Kidney Diseases at NIH and type 2 diabetes prevention and education programs for American Indians and Alaska Natives at the Indian Health Services. SDP is one of the Endocrine Society’s top priorities, and we have worked closely with the co-chairs of the Caucus to advocate for a long-term reauthorization of the Program. We need your help to urge your Members of Congress to reauthorize SDP and pass the INSULIN Act, which is bipartisan legislation that would make insulin more affordable for people on private insurance and the un-insured. We are asking all US-based Endocrine Society members to join our online campaign and urge your Representative and Senators to support these two important diabetes priorities. Please take action today. 

Society Releases Full Analysis of Medicare Physician Fee Schedule Rule for 2027

The Endocrine Society released a rule summary and final payment rates for the Medicare Physician Fee Schedule (MPFS) final rule for Calendar Year 2027. You can click here for the rule summary and here to download the payment rate chart. This annual rule updates payment policies and payment rates for Part B services furnished under the MPFS. Below are several highlights of the final rule. CMS estimates that the rule will have a net impact of +1% in total Medicare payments for the endocrinology specialty. The final rule also includes a provision that will increase payments for Final Needle Aspiration (FNA), a procedure performed by endocrinologists, by 20 percent. The Society strongly supported the FNA provision and worked with CMS to finalize this proposal. The final rule also includes a provision that eliminates the G2211 complex care add-on code and replaces it with a modifier. The Society urged CMS not to finalize the proposal eliminating the G2211 code because of the impact it would have on work RVUs for physicians. We are disappointed by this decision but will continue to advocate for CMS to address this issue. The Society commented on the proposed rule in September, and we worked closely with the Clinical Affairs Core Committee to develop our comments. The final rule will take effect on January 1, 202. 

Last Updated:
Take Action

Make Your Voice Heard

We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your US representatives or European Members of Parliament through our online platform. Take action and make a difference today.

We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your US representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.